Sökning: "small intestine neuroendocrine tumor"
Visar resultat 1 - 5 av 6 avhandlingar innehållade orden small intestine neuroendocrine tumor.
1. Profiling of Small Intestine Neuroendocrine Tumors
Sammanfattning : Small intestine neuroendocrine tumors (SI-NETs) are malignant neoplasms usually presenting with disseminated disease and symptoms of hormone overproduction. Radical surgery is curative but can only be performed for localized disease. For most patients the disease follows a progressive and fatal course. LÄS MER
2. Novel Circulating and Tissue Biomarkers for Small Intestine Neuroendocrine Tumors and Lung Carcinoids
Sammanfattning : Small intestine neuroendocrine tumors (SI-NETs) and lung carcinoids (LCs) are relatively indolent tumors, which originate from neuroendocrine (NE) cells of the diffuse NE system. Metastases can spread before diagnosis. Thus, potential cures become unavailable, which entitles new biomarker development. LÄS MER
3. lmprovement of 177Lu-octreotate treatment of small-intestine neuroendocrine tumors by hyperfractionation
Sammanfattning : Neuroendocrine tumor incidence is steadily rising, and the late diagnosis often results in metastatic disease and current treatments mostly prolong life and in-crease quality of life without increasing cure rate. 177Lu-octreotate was recently approved for treatment of neuroendocrine tumors, but the dosage scheme should be optimized. LÄS MER
4. Molecular aspects of tumor development and treatment for small intestinal neuroendocrine tumors
Sammanfattning : Small intestinal neuroendocrine tumors (SI-NETs) may cause symptoms due to excess secretion of hormones and peptides. The molecular mechanisms behind development of SINETs are not well understood. Copy number alterations, especially loss of chromosome 18q, have been reported and recently p27 mutations were implicated in SI-NET tumorigenesis. LÄS MER
5. Lutetium-177-octreotate treatment of small intestine neuroendocrine tumors - Radiation biology as basis for optimization
Sammanfattning : Patients with neuroendocrine tumors (NETs) often have metastatic spread at the time of diagnosis. NETs frequently express somatostatin receptors (SSTR) that can be targeted by radiolabeled somatostatin analogs (e.g. 177Lu-octreotate). LÄS MER